Yasutaka Ueda

Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study

Bruno Fattizzo, Irina Murakhovskaya, Yasutaka Ueda, Doug Schlichting et autres

Warm autoimmune hemolytic anemia (wAIHA) is a rare, life-threatening disease characterized by autoantibody-mediated destruction of red blood cells with no approved treatments. Nipocalimab, an immunoselective neonatal Fc receptor blocker, reduces circulating IgG levels, including autoantibodies implicated in wAIHA. The phase 2/3, randomized, …

it, us, jp (code pays fourni par la source)

Diagnostic delay and clinical outcomes of paroxysmal nocturnal hemoglobinuria: a retrospective cohort study using Japanese claims data

Yasutaka Ueda, Tatsuya Kawaguchi, Takayuki Ikezoe, Akihiko Shimono et autres

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, potentially life-threatening hematologic disease, often misdiagnosed because of its non-specific symptoms. PNH is characterized by terminal complement activity and intravascular hemolysis, potentially leading to thrombosis, kidney failure, and premature mortality. Early identification remains challenging, necessitating …

jp, ch (code pays fourni par la source)

MDS-1159: Long-Term Safety With Iptacopan Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Pooled Analysis of Data From Phase 2 and 3 Studies and the Roll-Over Extension Program

Alexander Röth, Austin Kulasekararaj, Camilla Frieri, Flore Sicre de Fontbrune et autres

de, gb, nl, it, fr, br, tw, es, jp, my, us, ch (code pays fourni par la source)

POSTER: MDS-748: Danicopan Add-On Therapy to Ravulizumab or Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis Stratified by Bone Marrow Failure History

Morag Griffin, Jin Seok Kim, Yasutaka Ueda, Flore Sicre-de-Fontbrune et autres

gb, kr, jp, fr, us (code pays fourni par la source)

MDS-748: Danicopan Add-On Therapy to Ravulizumab or Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis Stratified by Bone Marrow Failure History

Morag Griffin, Jin Seok Kim, Yasutaka Ueda, Flore Sicre-de-Fontbrune et autres

gb, kr, jp, fr, us (code pays fourni par la source)

POSTER: MDS-1159: Long-Term Safety With Iptacopan Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Pooled Analysis of Data From Phase 2 and 3 Studies and the Roll-Over Extension Program

Alexander Röth, Austin GKulasekararaj, Camilla Frieri, Flore Sicre de Fontbrune et autres

de, gb, nl, it, fr, br, tw, es, jp, my, us, ch (code pays fourni par la source)

Lifelong phylogenetic reconstruction of immune-mediated clonal trajectories in paroxysmal nocturnal hemoglobinuria

Hiroyuki Takamori, Yasutaka Ueda, Yoshikazu Matsuoka, Tatsuya Fujioka et autres

jp (code pays fourni par la source)

A small proportion of CD8 T cells expand robustly when stimulated with BCMAxCD3 bispecific T-cell engagers in vitro

Kumi Shibata, Kazuhito Tsutsumi, Hiraku Murakami, Emiko Mizuta et autres

jp (code pays fourni par la source)

On‐Chip Evaluation of Red Blood Cell Deformability Through Transit Velocity Index in Hematological Diseases

Kenji Kajitani, Chia-Hung Dylan Tsai, Tomohito Ohtani, Shigeo Wada et autres

ABSTRACT This study introduces a novel method for evaluating red blood cell (RBC) deformability using a microfluidic platform equipped with constriction channels that mimic capillary vessels. The normalized transit velocity of RBCs at 50% compression ratio (V^ ε = 0.5 ) is …

jp, tw, sk (code pays fourni par la source)

Disease burden and treatment patterns of paroxysmal nocturnal hemoglobinuria in Japan: a real-world survey

Masatoshi Sakurai, Yasutaka Ueda, Naoshi Obara, Michel Kroes et autres

This study aimed to determine the clinical profile and disease burden of patients with paroxysmal nocturnal hemoglobinuria (PNH) in Japan using real-world data from the Adelphi Real World PNH Disease Specific Programme (DSP)™, a cross-sectional survey conducted between January and December 2022. …

jp, ch, gb (code pays fourni par la source)

Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 Inhibitors

S. Gandhi, Markus P. Radsak, Yasutaka Ueda, M. Balp et autres

Objectives: To evaluate disease burden among paroxysmal nocturnal hemoglobinuria (PNH) patients prescribed C5 inhibitors (C5i). Methods: Data were drawn from the Adelphi Real World PNH Disease Specific Programme, a cross-sectional survey of physicians and PNH patients in Australia, Canada, France, Germany, Italy, …

gb, de, jp, ch (code pays fourni par la source)

Successful treatment of refractory DLBCL coexisting with SLE using Liso-cel, complicated by cytokine release syndrome

Kazuhiro Sanda, Kazuki Matsukawa, Akihisa Hino, Yumiko Mizuno et autres

Dear Editor, Lisocabtagene maraleucel (Liso-cel), a CD19-directed CAR-T therapy, is effective in relapsed or refractory high-grade B-cell lymphoma and has a low incidence of severe cytokine release syndrome (CRS) [1]. While recent studies have also demonstrated the efficacy of CD19 CAR-T therapies …

jp (code pays fourni par la source)